Women's responsiveness to the second-line breast cancer drug fulvestrant may depend on whether the cancer cells are expressing two key proteins, scientists report.
Breast cancer drug fulvestrant appears more effective in the presence of CK8 and CK18
Submitted by synapse on
Add new comment